Navigation Links
Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
Date:5/13/2009

ther group (P=0.006). The percentage of Osteoarthritis Research Society International (OARSI) responders for the EUFLEXXA(R) group was also significantly greater than that in the other group (67% versus 59% (P=0.047). A subject is considered a responder if there is a high improvement in pain or function, or improvement in at least two of the following three categories: pain greater than or equal to 20% and absolute change greater than or equal to 10 mm, function greater than or equal to 20% and absolute change greater than or equal to 10 mm, and/or patient global assessment greater than or equal to 20% and absolute change.

About EUFLEXXA(R)

EUFLEXXA(R) (1% sodium hyaluronate) is the first non-avian derived* hyaluronic acid (HA) approved in the U.S. for treatment of knee pain due to osteoarthritis (OA). EUFLEXXA(R) is indicated for patients who have failed to get adequate pain relief either from simple pain medications, such as acetaminophen, or from exercise and/or physical therapy. The process used to manufacture EUFLEXXA(R) results in highly-purified HA with properties similar to the HA in healthy human synovial fluid.(2-4) EUFLEXXA(R) received approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004, and became available to the public on November 8, 2005. For more information, visit www.EUFLEXXA.com.

EUFLEXXA(R) should not be used in people who have had any previous allergic reaction to hyaluronate preparations or who have knee joint infections or skin diseases in the area of the injection site. Common adverse events reported were arthralgia (joint pain) and back pain. Temporary knee pain and swelling may occur after injection. Strict aseptic technique must be followed to avoid joint infection.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmac
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... The Global Breast Pumps Market is ... an estimated CAGR of 7.6% from 2014 to 2020, according ... of innovative technologies including hand free breast pumps, growing women ... advantages of breast milk are expected to drive breast pump ... untapped growth opportunities in emerging markets such as ...
(Date:7/7/2015)... China , July 7, 2015 /PRNewswire/ -- Mindray ... a leading developer, manufacturer and marketer of medical ... acquire the remaining stake in Wuhan Dragonbio Surgical ... Dragonbio is a domestic medical ... and other surgical products. Prior to today,s announcement, ...
(Date:7/7/2015)... July 7, 2015 EnteroMedics Inc. (NASDAQ: ... use neuroblocking technology to treat obesity, metabolic diseases, and ... announced public offering of 32,000,000 units. Each unit consists of ... warrant to purchase one share of common stock at ... purchase of units in the offering would result in ...
Breaking Medicine Technology:Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
(Date:7/7/2015)... ... 07, 2015 , ... Leading healthcare consulting firm Hammes Company ... Vice President, heading the firm’s Healthcare Advisory Services division. , Mr. Warden will ... providers’ needs in ways that strengthen their position in the marketplace. The Healthcare ...
(Date:7/7/2015)... ... ... a reputable source of authentic tickets for the 2015 CONCACAF Gold Cup Group A matches ... Stadium. , The 2015 CONCACAF Gold Cup is now upon us as Group A ... soil, will kick off in Frisco, CA from the Toyota Stadium and will feature two ...
(Date:7/7/2015)... ... July 07, 2015 , ... Greatist today announced the ... helps active people find the most fun activities to do with friends. , The ... It also increases Greatist’s opportunity for events, e-commerce, and brand partnerships. , “I’ve been ...
(Date:7/7/2015)... N.J. (PRWEB) , ... July ... ... CTLT), the leading global provider of advanced delivery technologies and development solutions ... signed an exclusive licensing agreement with Excelimmune, Inc. to access its antibody ...
(Date:7/7/2015)... ... July 07, 2015 , ... Healthpointe is ... team. Dr. Alupay, an anesthesiologist and pain management specialist, will be evaluating and treating ... as neurological conditions. , After receiving his Bachelor of Science in Biology from the ...
Breaking Medicine News(10 mins):Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 2Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3
... CHICAGO, Sept. 18 As economic, social and political ... state,s leading provider of addiction treatment services is expanding its ... afford expensive clinics but also fail to qualify for government-funded ... a 41-year-old non-profit organization, serves more than 29,000 patients in ...
... feelings of isolation remains unclear , FRIDAY, Sept. 18 (HealthDay ... suicide and rural communities that have higher numbers of bars. ... mean more suicides because it does not show cause and ... percent are alcoholics, according to background information in a news ...
... , SAN FRANCISCO, Sept. 18 VIA ... focused on the development of compounds for the treatment of ... 2009, it received a deficiency letter from the NASDAQ Stock ... the minimum $1.00 per share bid price requirement for continued ...
... , BROOMFIELD, Colo., Sept. 18 Accera, Inc., ... today announced today that it will present at the UBS Global ... , Steve Orndorff, Ph.D., founder, president and CEO, ... Axona (TM) on Monday, September 21 at 11:30 a.m. EDT. ...
... , , WASHINGTON, Sept. 18 ... plan by Senate Finance Chairman Max Baucus, DMLR Chairman Stuart L. ... "The plan released by Senator Baucus is inadequate in addressing the ... and Democrats in the Congress, health care policy experts, opinion leaders, ...
... , BELLEVUE, Wash., Sept. 18 ... today extended its Edifecs5010(TM) Compliance S ... Comparison Manual , a comprehensive version analysis resource that ... changes and includes valuable insights from Subject Matter Experts illuminating ...
Cached Medicine News:Health News:Gateway Responding To Increased Need for Treatment Among Middle-Income Substance Abusers 2Health News:Suicides Higher in Rural Areas With Bars 2Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 2Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 3Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 4Health News:Accera, Inc. to Present at UBS Global Life Sciences Conference 2Health News:Statement From Stuart L. Weinstein, MD, Chairman, Doctors for Medical Liability Reform on Senator Baucus' Health Care Reform Proposal 2Health News:Edifecs Extends Its Edifecs5010(TM) Compliance Suite with the Launch of the Edifecs5010(TM) Comparison Manual, a Comprehensive Version Analysis Resource for HIPAA 5010 Migration. 2
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment....
The Boss Image-Trac system provides superior exposure for all surgical procedures from T1 to S1....
The Unitrac Retraction System is a pneumatic device that provides absolute rigid retraction and stable positioning to the operating room, freeing the surgical assistant to carry out higher priority t...
... Graft represents an rhBMP-2 (recombinant human bone ... bovine-derived absorbable collagen sponge (ACS) carrier. The ... is indicated for spinal fusion procedures in ... (DDD) at one level from L4-S1, who ...
Medicine Products: